To be included, patients must have had a microbiologically confirmed MRSA cSSTI (e.g., deep or extensive cellulitis, infected wound or ulcer, major abscess or other soft tissue infection requiring substantial surgical intervention), and received [greater than or equal to]3 days of IV anti-MRSA antibiotics including, but not limited to: clindamycin, daptomycin, fusidic acid, linezolid, rifampicin, teicoplanin, tigecycline, TMP/SMX, or vancomycin, during their hospital stay.
Treatment patterns analyzed included time to MRSA-active treatment from cSSTI index date and number of MRSA-active treatment received.
The company added that oritavancin is an investigational single dose intravenous antibiotic for the planned treatment of cSSTI (known as acute bacterial skin and skin structure infections (ABSSSIs) in the US) that is caused by susceptible gram-positive bacteria, including MRSA.
These Phase 3 trials evaluated the efficacy and safety of a single 1200 mg dose of oritavancin compared to seven to ten days of twice-daily vancomycin in adults with cSSTI, including infections caused by MRSA.
The researchers compared 482 children with uncomplicated SSTIs and 98 children with complicated SSTIs (cSSTIs
) who were admitted to a single hospital between Jan.
It is also not an appropriate empiric option as monotherapy for the treatment of patients with cSSTI
* Cure rates in clinically evaluable patients hospitalised with cSSTI
were also similar for those treated with tigecycline and those treated with vancomycin plus aztreonam (87%, N=422 v.
Pharmaceutical company Durata Therapeutics Inc (NasdaqGM :DRTX) said on Tuesday that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for the marketing and sale of dalbavancin for the treatment of patients with complicated skin and soft tissue infections (cSSTI
In cases of multiple infections, investigators entered the type of infection in order of clinical significance (in order of most to least severe): endocarditis, osteomyelitis, bacteremia, other [CNS infection, foreign body/prosthetic infection, metastatic abscess, necrotizing fasciitis, necrotizing infection, surgical/non-surgical antibiotic prophylaxis, septic arthritis and urinary tract infection/pyelonephritis], cSSTI
, and uncomplicated skin and soft tissue infection.
The emergence of drug-resistant bacteria causing CAP and cSSTI
has increased the potential for inappropriate initial therapy in these infections.
The CHMP had adopted a negative opinion on the MAA for ceftobiprole for the treatment of cSSTI
on 18 February 2010.